HCPCS code J1725 – Hydroxyprogesterone caproate injection, 1 mg

Key takeaways

HCPCS Code J1725 describes injection, hydroxyprogesterone caproate, 1 mg, and CMS deleted it with effect from December 31, 2017.

For dates of service from January 1, 2018, bill J1726 for Makena or J1729 for other hydroxyprogesterone caproate products.

J1725 counted 1 unit per mg, while J1726 and J1729 count 1 unit per 10 mg, so a 250 mg dose is 25 units.

The FDA withdrew approval of Makena and its generics in April 2023, so confirm coverage with the payer before any claim.

Pair the drug code with a trimester-specific ICD-10-CM code, such as O09.212, that documents a prior preterm birth.

HCPCS Code J1725: Definition and code description

HCPCS Code J1725 is a deleted Level II drug code whose official descriptor reads: Injection, hydroxyprogesterone caproate, 1 mg. CMS added it on January 1, 2012 and terminated it on December 31, 2017. The dates come from the Centers for Medicare and Medicaid Services (CMS) HCPCS code file.

J1725 is therefore not valid for any date of service from January 1, 2018. The drug moved to two 10 mg codes on that date. J1726 covers the Makena brand, and J1729 covers hydroxyprogesterone caproate not otherwise specified.

J1725 still turns up in three places:

• Older claims under audit or appeal
• Legacy charge masters that were never updated
• Historical reports that mix 1 mg and 10 mg units

J1725 code details at a glance

What hydroxyprogesterone caproate was used for

Hydroxyprogesterone caproate (also called 17-OHPC or 17P) is a synthetic progestin. It was given to reduce the risk of preterm birth in patients with a singleton pregnancy and a history of singleton spontaneous preterm birth.

The labeled regimen was 250 mg by weekly intramuscular injection. Treatment started between 16 weeks 0 days and 20 weeks 6 days of gestation and continued until week 37 or delivery. A 275 mg subcutaneous auto-injector of Makena was added later.

OB/GYN and maternal-fetal medicine practices were the main billers of this drug. An audit of these claims turns on their records of obstetric history and gestational age.

Is J1725 still valid? Code status and replacement codes

No, J1725 is not valid for current claims. CMS terminated it on December 31, 2017, and a claim line carrying it for a later date of service is rejected as an invalid code.

CMS first split the drug with two temporary codes from July 1, 2017. Q9986 covered Makena, and Q9985 covered hydroxyprogesterone caproate not otherwise specified. On January 1, 2018 those Q-codes and J1725 were all retired, and J1726 and J1729 took over. Medicare Part B stopped accepting J1725 earlier, on July 1, 2017, when the Q-codes began, per CMS transmittal R3776CP. The timeline below shows when each code applied and what a 250 mg dose bills as.

Decision rule: Start from the date of service, then the product. Makena, in either the vial or the auto-injector, maps to J1726. Any other hydroxyprogesterone caproate product maps to J1729.

Unit billing: Converting the dose to units

The unit size is where J1725 and its replacements differ most. J1725 counted 1 unit per mg, so a 250 mg dose was billed as 250 units. J1726 and J1729 count 1 unit per 10 mg, so the same dose is 25 units.

• J1725, 250 mg dose (dates of service through 2017): 250 units
• J1726 or J1729, 250 mg dose: 25 units
• Makena auto-injector, 275 mg dose: 27.5 units on J1726, rounded according to the payer’s unit rules
• Units field: Enter the unit count in Box 24G of the CMS-1500 form, never the milligram dose

Carrying the old 1 mg habit over to the new codes is the costly mistake. Billing 250 units of J1726 claims ten times the dose given, which can trigger a medically unlikely edit or an overpayment recovery.

The same dose-to-unit error shows up on other obstetric drug codes. J2210, methylergonovine maleate, bills one unit per 0.2 mg vial, so a note reading 200 mcg is one unit, not 200.

The 2023 Makena withdrawal and what it means for billing

The FDA withdrew approval of Makena and its generic versions on April 6, 2023. A confirmatory trial had not shown a clinical benefit, and the products can no longer be lawfully distributed in interstate commerce.

J1726 and J1729 remain in the HCPCS file, but no FDA-approved product now sits behind them. Many payers ended coverage after the withdrawal. Confirm the payer’s current policy in writing before any administration, not after.

Compounded hydroxyprogesterone caproate

Compounded hydroxyprogesterone caproate has no dedicated HCPCS code of its own. Payers that cover a compounded drug set their own rules for which code and documentation they accept.

Medicare Part B covers compounded drugs only in limited circumstances. Check your Medicare Administrative Contractor’s (MAC) policy and the payer’s written guidance before billing compounded 17P under any code.

NDC reporting requirements

The National Drug Code (NDC) is the 11-digit identifier of the drug product and package. Medicaid programs require it on claims for physician-administered drugs, and many commercial payers ask for it too. A missing or mismatched NDC is a common reason drug claims are denied.

The NDC also tells the payer which product was given. A Makena NDC belongs on a J1726 line, and a generic NDC belongs on a J1729 line. A mismatch between the two is an easy edit for a payer to catch.

ICD-10-CM diagnosis codes paired with hydroxyprogesterone caproate

Payers look for a diagnosis that matches the labeled indication: a current singleton pregnancy in a patient with a prior spontaneous preterm birth. The ICD-10-CM codes below are the ones most often used to document it.

O09.21 on its own is not a valid billing code. Submit the full trimester code, such as O09.212 for the second trimester, or the claim is rejected before payer review.

Reimbursement and the administration code

Medicare Part B pays most physician-administered drugs at the Average Sales Price (ASP) plus 6%. CMS publishes the rates in its quarterly ASP pricing files. J1725 has no current payment rate because the code is deleted.

• Administration code: Report CPT 96372 for the intramuscular or subcutaneous injection service.
• Place of service: Most weekly injections were given in the office (POS 11), and the POS code affects the rate paid.
• Medicaid: Rates and coverage vary by state, so check your state Medicaid fee schedule.

Documentation requirements

Payers that cover hydroxyprogesterone caproate usually require prior authorization. The medical record has to support both the indication and each dose billed.

• Obstetric history confirming at least one prior spontaneous preterm birth, with the gestational age at that delivery
• Confirmation of a current singleton pregnancy
• Gestational age when treatment started
• The order, with drug, dose in mg, frequency and route
• The NDC and lot number of the product given on each date of service
• An administration note with injection site, dose and time
• The payer’s authorization number and its coverage dates

Keep these records for the full retention period your payer contracts and state rules set. A post-payment audit of 2017 claims will test the J1725 units against the dose recorded.

Common billing errors and claim denials

Most denials on this drug trace back to the 2018 code change or the 2023 withdrawal. The table pairs each common error with its fix.

Tracking these denials by reason code shows whether they cluster around one cause. Denial management workflows make that pattern visible before it spreads.

How Pabau supports documentation for injectable drug billing

Injectable drug claims stand or fall on the record behind them. When the obstetric history, the dose and the product details sit in separate files, an authorization request or an audit means hours of searching.

Pabau, the all-in-one practice management system we build, keeps patient records, treatment notes, consent forms and invoices together. Staff can record the dose and product details in the treatment note for each visit, next to the patient’s history.

For practices that bill insurers, Pabau also offers claims management software built on the same patient record.

Keep drug claims backed by complete records

Pabau keeps the treatment note, the patient’s history and the invoice in one record. Billing staff can confirm the dose and product behind every injectable drug claim.

Book a demo

Conclusion

J1725 belongs to claims from 2012 through 2017 and nowhere else. Remove it from your charge master, and map any remaining hydroxyprogesterone caproate charges to J1726 or J1729 at 10 mg per unit.

The bigger risk now is coverage rather than coding. With no approved product on the market since April 2023, a payer’s written policy decides whether a claim is paid. Book a demo to see how Pabau keeps the record behind every drug claim in one place.

Continue your research

Need a complete picture of how denials flow through your revenue cycle? Denial management in healthcare covers how to categorize, track, and appeal claim denials systematically.

Looking for a structured billing workflow for injectable drugs? What is medical billing explains how the end-to-end billing process works for physician-administered drugs.

Want to understand how electronic claim submission works for J-codes? Superbill creation and claim submission covers how charge capture connects to the clearinghouse claim file.

Frequently asked questions